Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Experience with Optivate®, a new high purity concentrate of factor VIII with von Willebrand factor, in patients undergoing surgery.

Hay CR, Hellmann A, Dmoszynska A, Baglin T, O'Shaunessey D, Makris M, Shaikh-Zaidi R, Dash CH.

Haemophilia. 2011 May;17(3):428-32. doi: 10.1111/j.1365-2516.2010.02441.x. Epub 2011 Mar 3.

PMID:
21371182
2.

Clinical assessment of Optivate®, a high-purity concentrate of factor VIII with von Willebrand factor, in the management of patients with haemophilia A.

Dmoszynska A, Kuliczkowski K, Hellmann A, Trelinski J, Kloczko J, Baglin T, Hay C, O'Shaughnessy D, Zawilska K, Makris M, Shaikh-Zaidi R, Gascoigne E, Dash C.

Haemophilia. 2011 May;17(3):456-62. doi: 10.1111/j.1365-2516.2010.02446.x. Epub 2011 Mar 4.

PMID:
21371184
3.

Successful surgical haemostasis in patients with von Willebrand disease with Koate DVI.

Viswabandya A, Mathews V, George B, Nair SC, Baidya S, Mammen JJ, Chandy M, Srivastava A.

Haemophilia. 2008 Jul;14(4):763-7. doi: 10.1111/j.1365-2516.2008.01755.x. Epub 2008 Apr 24.

PMID:
18445014
4.

Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.

Klukowska A, Windyga J, Batorova A.

Thromb Res. 2011 Mar;127(3):247-53. doi: 10.1016/j.thromres.2010.11.030. Epub 2011 Jan 8.

PMID:
21220152
5.

Clinical experience with Optivate®, high-purity factor VIII (FVIII) product with von Willebrand factor (VWF) in young children with haemophilia A.

Matysiak M, Bobrowska H, Balwierz W, Chybicka A, Kowalczyk JR, Shaikh-Zaidi R, Gillanders K, Dash CH.

Haemophilia. 2011 Sep;17(5):737-42. doi: 10.1111/j.1365-2516.2011.02600.x. Epub 2011 Jun 23.

PMID:
21699629
6.

Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery.

Windyga J, von Depka-Prondzinski M; European Wilate® Study Group.

Thromb Haemost. 2011 Jun;105(6):1072-9. doi: 10.1160/TH10-10-0631. Epub 2011 Mar 24.

PMID:
21437358
7.

Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.

Franchini M, Rossetti G, Tagliaferri A, Pattacini C, Pozzoli D, Lippi G, Manzato F, Bertuzzo D, Gandini G.

Haematologica. 2003 Nov;88(11):1279-83.

8.

The clinical efficacy and safety of the FVIII/VWF concentrate, BIOSTATE®, in children with von Willebrand disorder: a multi-centre retrospective review.

Howman R, Barnes C, Curtin J, Price J, Robertson J, Russell S, Seldon M, Suppiah R, Teague L, Barrese G.

Haemophilia. 2011 May;17(3):463-9. doi: 10.1111/j.1365-2516.2010.02445.x. Epub 2010 Dec 1.

PMID:
21118340
9.

Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A.

Dmoszynska A, Hellmann A, Baglin T, O'Shaugnessy D, Trelinski J, Kuliczkowski K, Kloczko J, Hay C, Zawilska K, Makris M, Shaikh-Zaidi R, Gascoigne E, Dash C.

Haemophilia. 2011 Mar;17(2):185-90. doi: 10.1111/j.1365-2516.2010.02414.x. Epub 2010 Nov 11.

PMID:
21070496
10.

Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.

Federici AB, Baudo F, Caracciolo C, Mancuso G, Mazzucconi MG, Musso R, Schinco PC, Targhetta R, Mannuccio Mannucci P.

Haemophilia. 2002 Nov;8(6):761-7.

PMID:
12410644
11.

Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia.

Martinowitz U, Luboshitz J, Bashari D, Ravid B, Gorina E, Regan L, Stass H, Lubetsky A.

Haemophilia. 2009 May;15(3):676-85. doi: 10.1111/j.1365-2516.2008.01978.x. Epub 2009 Feb 27.

PMID:
19298381
12.

Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi a highly purified, doubly inactivated FVIII/VWF concentrate.

Hernandez-Navarro F, Quintana M, Jimenez-Yuste V, Alvarez MT, Fernandez-Morata R.

Haemophilia. 2008 Sep;14(5):963-7. doi: 10.1111/j.1365-2516.2008.01784.x. Epub 2008 Jul 9.

PMID:
18624696
13.

Efficacy of factor VIII/von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery in subjects with von Willebrand disease.

Rivard GE, Aledort L; Alphanate Surgical Investigators.

Haemophilia. 2008 Mar;14(2):271-5. doi: 10.1111/j.1365-2516.2007.01616.x. Epub 2008 Jan 8.

PMID:
18194310
14.

Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study.

Dunkley S, Baker RI, Pidcock M, Price J, Seldon M, Smith M, Street A, Maher D, Barrese G, Stone C, Lloyd J.

Haemophilia. 2010 Jul 1;16(4):615-24. doi: 10.1111/j.1365-2516.2010.02206.x. Epub 2010 Mar 16.

PMID:
20331755
15.

Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.

Berntorp E, Windyga J; European Wilate Study Group.

Haemophilia. 2009 Jan;15(1):122-30. doi: 10.1111/j.1365-2516.2008.01901.x.

PMID:
19149848
16.

Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).

Michiels JJ, Berneman ZN, van der Planken M, Schroyens W, Budde U, van Vliet HH.

Blood Coagul Fibrinolysis. 2004 Jun;15(4):323-30.

PMID:
15166918
17.

Elective surgery in patients with congenital coagulopathies and inhibitors: experience of the National Haemophilia Centre of Venezuela.

Boadas A, Fernández-Palazzi F, De Bosch NB, Cedeño M, Ruiz-Sáez A.

Haemophilia. 2011 May;17(3):422-7. doi: 10.1111/j.1365-2516.2010.02427.x. Epub 2010 Dec 1.

PMID:
21118333
18.

The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A.

Lusher JM, Lee CA, Kessler CM, Bedrosian CL; ReFacto Phase 3 Study Group.

Haemophilia. 2003 Jan;9(1):38-49.

PMID:
12558777
19.
20.

Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P).

Thompson AR, Gill JC, Ewenstein BM, Mueller-Velten G, Schwartz BA; Humate-P Study Group.

Haemophilia. 2004 Jan;10(1):42-51.

PMID:
14962219
Items per page

Supplemental Content

Write to the Help Desk